FAACS: Feasibility/Acceptability of Attentional-Control Training in Survivors
FAACS:幸存者注意力控制训练的可行性/可接受性
基本信息
- 批准号:10458355
- 负责人:
- 金额:$ 28.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Academic achievementAcute Lymphocytic LeukemiaAddressAffectAgeAttentionAttention deficit hyperactivity disorderBehaviorBostonBrain NeoplasmsChildChildhood Acute Lymphocytic LeukemiaChildhood Brain NeoplasmClinical TrialsCognitiveCognitive remediationControl GroupsCranial IrradiationDataDiseaseEnrollmentEnvironmentExcisionFDA approvedFamilyGoalsHomeImpairmentInterventionIntervention StudiesLate EffectsLearningLettersLifeLightMalignant Childhood NeoplasmMeasuresMethotrexateNeuraxisOutcomeParentsParticipantPatientsPediatric OncologyPerformancePersonsPilot ProjectsPopulationQuality of lifeQuestionnairesRadiation therapyRandomizedRandomized Controlled TrialsRegulationResearchRiskSavingsSchoolsShort-Term MemorySiteSocializationStructureSurvival RateSurvivorsTablet ComputerTestingThinkingTimeTrainingTraining ProgramsYouthacceptability and feasibilityactive controlattentional controlbaseblood-brain barrier crossingcancer therapychemotherapychildhood cancer survivorcognitive abilitycognitive developmentcognitive functioncognitive loadcognitive skillcognitive trainingcohortcompliance behaviordesigndigitalefficacy trialexecutive functionexperiencefunctional improvementimprovedinterestneurocognitive testperformance based measurementpost interventionprogramsrandomized trialrelating to nervous systemsatisfactionskillssocial relationshipsspellingtechnical reporttreatment adherencetreatment effecttumor
项目摘要
PROJECT SUMMARY/ABSTRACT
Survival rates are increasing for common pediatric cancers, including acute lymphoblastic leukemia (ALL) and
brain tumors; yet the life-saving treatments for these cancers place survivors at heightened risk for sustained
cognitive effects. Longitudinal research has shown that the cognitive burden of ALL and pediatric brain tumors
may consist of impairments in attention, working memory, and executive functioning, which results in long-term
disruption to daily living, socialization, academic achievement, and quality of life. Few non-pharmacological
interventions exist to ameliorate these cognitive late effects, but the results have been promising. The most
widely studied intervention, Cogmed, is an electronic cognitive training program that has been shown to
improve working memory, but has not resulted in broad functional improvement. Thus, it may be that a multi-
domain approach is needed to generalize treatment effects to real-world functioning. Endeavor, an FDA-
approved electronic attentional-control training program, may be one intervention to help compensate for the
executive functioning difficulties experienced by survivors. Although the program has been efficacious for youth
with Attention-Deficit/Hyperactivity Disorder (ADHD), it has not yet been tested among survivors of childhood
ALL or brain tumor. Therefore, a pilot randomized controlled trial is proposed to assess the feasibility,
acceptability, and preliminary efficacy of Endeavor. Survivors of ALL or brain tumor who are between the ages
of 8 and 16 and have been off-therapy for at least one year will be included. The goal is to enroll 40
participants across three pediatric oncology centers. Patients will participate in either the Endeavor
intervention, which includes 25-30 minute sessions per day, 5 days per week, for one month, or an active
control condition. Patients will undergo neurocognitive testing pre- and post-intervention, and parents will
complete questionnaires regarding their child’s functioning. It is hypothesized that this attentional-control
training program will be both acceptable and feasible, with sufficient enrollment, positive satisfaction ratings,
and at least 80% treatment compliance. It is also anticipated that participants will show increases in
performance-based and parent-rated attention, as compared to those in the active control condition. These
results will be essential to our conceptualization of the utility of Endeavor and will inform a larger randomized
trial of the efficacy of this training program. Taken together, this pilot study will have important implications for
the development of cognitive remediation options for survivors of childhood ALL and brain tumor.
项目总结/摘要
常见儿科癌症的生存率正在增加,包括急性淋巴细胞白血病(ALL)和
脑肿瘤;然而,对这些癌症的挽救生命的治疗使幸存者处于持续的高风险之中。
认知效应纵向研究表明,ALL和儿童脑肿瘤的认知负担
可能包括注意力、工作记忆和执行功能的损害,这导致长期的
对日常生活、社交、学术成就和生活质量的破坏。非药物治疗很少
存在可以改善这些认知晚期效应的干预措施,但结果是有希望的。最
广泛研究的干预,Cogmed,是一种电子认知训练计划,已被证明,
改善工作记忆,但没有导致广泛功能改善。或许,这是一个多方面的问题。
需要领域方法来将治疗效果推广到现实世界的功能。奋进,一个FDA-
批准的电子注意力控制训练计划,可能是一种干预,以帮助补偿
幸存者经历的执行功能障碍。尽管该计划对年轻人有效,
注意力缺陷多动障碍(ADHD),它尚未在儿童幸存者中进行测试。
ALL或脑瘤。因此,拟进行一项初步随机对照试验,以评估其可行性,
奋进的可接受性和初步疗效。年龄介于以下的ALL或脑肿瘤幸存者
8岁和16岁,并且已经停止治疗至少一年。目标是招收40名
三个儿科肿瘤中心的参与者。患者将参加奋进
干预,包括每天25-30分钟的课程,每周5天,为期一个月,或
控制条件患者将在干预前后接受神经认知测试,父母将
填写关于孩子功能的问卷。据推测,这种注意力控制
培训计划既可接受又可行,有足够的报名人数,积极的满意度评级,
以及至少80%的治疗依从性。预计参加者的人数也将增加,
与主动控制条件下的注意力相比,基于表现的注意力和父母评定的注意力。这些
这些结果对于我们对奋进号实用性的概念化至关重要,并将为一个更大的随机
测试这个训练计划的效果。总之,这项试点研究将对以下方面产生重要影响:
为儿童ALL和脑肿瘤幸存者开发认知补救方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven Hardy其他文献
Steven Hardy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven Hardy', 18)}}的其他基金
FAACS: Feasibility/Acceptability of Attentional-Control Training in Survivors
FAACS:幸存者注意力控制训练的可行性/可接受性
- 批准号:
10684249 - 财政年份:2022
- 资助金额:
$ 28.91万 - 项目类别:
Trajectory of Cognitive Functioning in Youth with Sickle Cell Disease without Cerebral Infarction
患有镰状细胞病(不伴脑梗塞)的青年人的认知功能轨迹
- 批准号:
10580792 - 财政年份:2019
- 资助金额:
$ 28.91万 - 项目类别:
Trajectory of Cognitive Functioning in Youth with Sickle Cell Disease without Cerebral Infarction
患有镰状细胞病(不伴脑梗塞)的青年人的认知功能轨迹
- 批准号:
10163896 - 财政年份:2019
- 资助金额:
$ 28.91万 - 项目类别:
Trajectory of Cognitive Functioning in Youth with Sickle Cell Disease without Cerebral Infarction
患有镰状细胞病(不伴脑梗塞)的青年人的认知功能轨迹
- 批准号:
10349583 - 财政年份:2019
- 资助金额:
$ 28.91万 - 项目类别:
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 28.91万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 28.91万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 28.91万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 28.91万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 28.91万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 28.91万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 28.91万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 28.91万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 28.91万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 28.91万 - 项目类别: